<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01361789</url>
  </required_header>
  <id_info>
    <org_study_id>2004_01927 COX</org_study_id>
    <nct_id>NCT01361789</nct_id>
  </id_info>
  <brief_title>COX-2 Inhibitor Versus Glucocorticoid Versus Both Combined</brief_title>
  <official_title>COX-2 Inhibitor Versus Glucocorticoid Versus Both Combined</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asker &amp; Baerum Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asker &amp; Baerum Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent studies on molar surgery have shown that a combination of a glucocorticoid and NSAID
      or COX-2 selective inhibitor gives better pain relief than either of the drugs used
      separately. The investigators group has also shown that adding dexamethasone on top of a
      regimen of paracetamol, NSAID and local anesthesia resulted in 45% painfree patients at rest
      after ambulatory breast cancer surgery.

      The goal of this study is to test the NSAID + glucocorticoid concept in ACl repair. The
      investigators want to evaluate whether a selective COX-2 selective inhibitor or a
      glucocorticoid or a combination of both drugs, as part of a multimodal analgesic regime, can
      provide improved pain relief and shorter hospital stay in patients undergoing outpatient ACL
      surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative VAS score at rest 24 hours after surgery</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulated opioid consumption</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">93</enrollment>
  <condition>Rupture of Anterior Cruciate Ligament</condition>
  <arm_group>
    <arm_group_label>COXIB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>40 mg parecoxib (Dynastat, Pfizer速) one hour before surgery and 40 mg valdecoxib (prodrug of parecoxib, Bextra, Pfizer速)were given 8 hour after surgery.
After retraction of parecoxib from the market:
Etoricoxib (Arcoxia, MSD) 120 mg given one hour before surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>dexamethasone 8 mg iv</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COXIB and dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>combination of coxib AND dexamethasone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>parecoxib, valdecoxib, etoricoxib</intervention_name>
    <description>40 mg parecoxib (Dynastat, Pfizer速) one hour before surgery and 40 mg valdecoxib (prodrug of parecoxib, Bextra, Pfizer速)were given 8 hour after surgery.
After retraction of parecoxib from the market:
Etoricoxib (Arcoxia, MSD) 120 mg given one hour before surgery</description>
    <arm_group_label>COXIB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>8 mg IV</description>
    <arm_group_label>Dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>parecoxib, valdecoxib, parecoxib and dexamethasone</intervention_name>
    <description>combination of both drugs</description>
    <arm_group_label>COXIB and dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Arthroscopic reconstruction of the anterior crucial ligament (ACL)

          -  At least 18 years old

          -  ASA I + II

        Exclusion Criteria:

          -  Known renal impairment

          -  Liver failure and/-or an asthmatic condition

          -  Pregnancy

          -  Breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vegard Dahl, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baerum Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ulrich J Spreng, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baerum Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baerum Hospital</name>
      <address>
        <city>Rud</city>
        <zip>1309</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2011</study_first_submitted>
  <study_first_submitted_qc>May 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2011</study_first_posted>
  <last_update_submitted>May 26, 2011</last_update_submitted>
  <last_update_submitted_qc>May 26, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2011</last_update_posted>
  <responsible_party>
    <name_title>Baerum Hospital</name_title>
    <organization>Vestre Viken HF</organization>
  </responsible_party>
  <keyword>Arthroscopic reconstruction</keyword>
  <keyword>Anterior crucial ligament</keyword>
  <keyword>Coxib</keyword>
  <keyword>Dexamethasone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rupture</mesh_term>
    <mesh_term>Anterior Cruciate Ligament Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Etoricoxib</mesh_term>
    <mesh_term>Parecoxib</mesh_term>
    <mesh_term>Valdecoxib</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Glucocorticoids</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Cyclooxygenase 2 Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

